Candel Positive Interim Data from Phase 2 Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

 

• Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409
• Estimated overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm after chemoradiation
• In patients with progressive disease, there was both a CA19-9 and a survival response to salvage chemotherapy in the CAN-2409 arm, but not in the control arm.
• Dense aggregates of immune cells, including CD8 positive granzyme B positive cytotoxic T cells, dendritic cells, and B cells, were observed in PDAC tissue after CAN-2409 treatment, confirming activation of a robust antitumoral immune response
• Safety analysis demonstrated that multiple injections of CAN-2409 were generally well tolerated, with no reported dose-limiting toxicities and no cases of pancreatitis

https://www.globenewswire.com/news-release/2023/11/03/2773326/0/en/Candel-Therapeutics-Announces-Initial-Positive-Interim-Data-from-Randomized-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Metastatic-Pancreatic-Cancer.html